Huayi Pharmaceutical (Guangdong) Co., Ltd. Obtains Radioactive Pharmaceutical Production License
On April 11, 2025, Huayi Pharmaceutical (Guangdong) Co., Ltd. successfully obtained the “Radioactive Pharmaceutical Production License” issued by the National Medical Products Administration. This marks a key milestone in the company’s national layout and signifies a new level of industrialization capability in the field of radiopharmaceuticals.
Huayi Pharmaceutical (Guangdong) Co., Ltd. is a crucial production platform established by Jiangsu Huayi Technology Co., Ltd. in the South China region. It undertakes the company’s national network strategy of “multi - center deployment and rapid response”. The successful acquisition of the license will effectively support the clinical application, product distribution, and scientific research cooperation of radiopharmaceuticals in the South China region.
The production of radiopharmaceuticals is a highly specialized field that requires strict compliance with national GMP standards and radiation safety management requirements. During the construction process, Huayi Pharmaceutical (Guangdong) adhered to high standards in all aspects, including plant layout, equipment selection, personnel training, and quality control, to ensure the safety, compliance, and efficiency of the entire pharmaceutical production process.
With the acquisition of this license, Huayi Technology has formed a coverage network of multiple compliant radiopharmaceutical production centers in China. This network provides stronger delivery and risk - response capabilities, enabling the company to offer more flexible and diverse cooperation models to customers.
The completion and operation of Huayi Pharmaceutical (Guangdong) is not only a milestone in the company’s pursuit of high - quality development but also an active response to the development needs of the radiopharmaceutical industry. In the future, we will continue to optimize the regional supply system, accelerate the speed of achievement transformation, expand cooperation models, and provide better products and services for clinical use.